Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

Similar articles for PubMed (Select 20925551)

1.

Autoimmunity in a genetic disease—a cautionary tale.

Moore MJ, Flotte TR.

N Engl J Med. 2010 Oct 7;363(15):1473-5. doi: 10.1056/NEJMe1009056. No abstract available.

PMID:
20925551
2.

Dystrophin immunity in Duchenne's muscular dystrophy.

Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, McPhee SW, Samulski RJ, Walker CM.

N Engl J Med. 2010 Oct 7;363(15):1429-37. doi: 10.1056/NEJMoa1000228.

3.

Identification of an HLA-A*0201-restricted epitopic peptide from human dystrophin: application in duchenne muscular dystrophy gene therapy.

Ginhoux F, Doucet C, Leboeuf M, Lemonnier FA, Danos O, Davoust J, Firat H.

Mol Ther. 2003 Aug;8(2):274-83.

PMID:
12907150
4.

Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient.

Takeshima Y, Wada H, Yagi M, Ishikawa Y, Ishikawa Y, Minami R, Nakamura H, Matsuo M.

Brain Dev. 2001 Dec;23(8):788-90. No abstract available.

PMID:
11720794
5.
6.

Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy.

Wells DJ, Ferrer A, Wells KE.

Expert Rev Mol Med. 2002 Nov 4;4(23):1-23. Review.

PMID:
14585159
7.

Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice.

Braun S, Thioudellet C, Rodriguez P, Ali-Hadji D, Perraud F, Accart N, Balloul JM, Halluard C, Acres B, Cavallini B, Pavirani A.

Gene Ther. 2000 Sep;7(17):1447-57.

8.

Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.

Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A.

Hum Mol Genet. 2000 Oct 12;9(17):2507-15.

9.

Gene therapy for Duchenne muscular dystrophy: AAV leads the way.

Judge LM, Chamberlain JS.

Acta Myol. 2005 Dec;24(3):184-93. Review.

PMID:
16629052
10.

[Mutation-specific treatments for Duchenne muscular dystrophy].

Matsuo M, Takeshima Y.

Brain Nerve. 2009 Aug;61(8):915-22. Review. Japanese.

PMID:
19697880
11.

Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.

Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O.

Science. 2004 Dec 3;306(5702):1796-9. Epub 2004 Nov 4.

12.

Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.

Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC.

Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7.

PMID:
12206800
13.

Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.

Yuasa K, Yoshimura M, Urasawa N, Ohshima S, Howell JM, Nakamura A, Hijikata T, Miyagoe-Suzuki Y, Takeda S.

Gene Ther. 2007 Sep;14(17):1249-60. Epub 2007 Jun 21.

PMID:
17581597
14.

Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.

Yokota T, Pistilli E, Duddy W, Nagaraju K.

Expert Opin Biol Ther. 2007 Jun;7(6):831-42. Review.

PMID:
17555369
15.

Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector.

Gilchrist SC, Ontell MP, Kochanek S, Clemens PR.

Mol Ther. 2002 Sep;6(3):359-68.

PMID:
12231172
16.

The role of immunosuppression in gene- and cell-based treatments for duchenne muscular dystrophy.

Arruda VR.

Mol Ther. 2007 Jun;15(6):1040-1. No abstract available.

PMID:
17510638
17.

Dystrophin delivery in dystrophin-deficient DMDmdx skeletal muscle by isogenic muscle-derived stem cell transplantation.

Ikezawa M, Cao B, Qu Z, Peng H, Xiao X, Pruchnic R, Kimura S, Miike T, Huard J.

Hum Gene Ther. 2003 Nov 1;14(16):1535-46.

PMID:
14577915
18.

Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.

Cerletti M, Negri T, Cozzi F, Colpo R, Andreetta F, Croci D, Davies KE, Cornelio F, Pozza O, Karpati G, Gilbert R, Mora M.

Gene Ther. 2003 May;10(9):750-7.

PMID:
12704413
19.

[Frontline studies on Duchenne muscular dystrophy treatment].

Matsuo M.

No To Hattatsu. 2009 Mar;41(2):92-5. Review. Japanese.

PMID:
19517771
20.

Exon-skipping therapy for Duchenne muscular dystrophy.

Nakamura A, Takeda S.

Neuropathology. 2009 Aug;29(4):494-501. doi: 10.1111/j.1440-1789.2009.01028.x. Epub 2009 May 22. Review.

PMID:
19486303
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk